Evidence map›Paper›PMID 35398015›Full record

ReviewProgress in retinal and eye research2022

A novel glaucoma approach: Stem cell regeneration of the trabecular meshwork.

Sara J Coulon, Joel S Schuman, Yiqin Du, Mohammad Reza Bahrani Fard, C Ross Ethier, W Daniel Stamer

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Progress in retinal and eye research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Trabecular Meshwork Stem Cells for Glaucoma Treatment.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Sara J CoulonDepartment of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, USA.
Joel S SchumanDepartment of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, USA; Center for Neural Science, College of Arts and Science, New York University, New York, NY, USA; Departments of Biomedical Engineering and Electrical and Computer Engineering, New York University Tandon School of Engineering, Brooklyn, NY, USA; Department of Physiology and Neuroscience, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, USA. Electronic address: joel.schuman@nyu.edu.
Yiqin DuDepartment of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Mohammad Reza Bahrani FardWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, Atlanta, GA, USA.
C Ross EthierWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, Atlanta, GA, USA.
W Daniel StamerDepartments of Ophthalmology and Biomedical Engineering, Duke University, Durham, NC, USA.
Georgia Institute of Technology · USNew York University · USDuke University · USUniversity of Pittsburgh · US

Funding

Mechanisms of Trabecular Meshwork Regeneration by Stem CellsR01EY025643 · NEI · UNIVERSITY OF SOUTH FLORIDA · PI Yiqin Du · 2015 to 2026
$4.2M
Transcriptional and Biomechanical Analysis of Segmental Outflow in GlaucomaR01EY031710 · NEI · GEORGIA INSTITUTE OF TECHNOLOGY · PI ETHIER, C ROSS, GUPTA, DIVAKAR · 2020 to 2023
$2.4M
Magnetic Steering and Longitudinal Visualization of Stem Cells for Trabecular Meshwork Therapy in GlaucomaR01EY030071 · NEI · GEORGIA INSTITUTE OF TECHNOLOGY · PI EMELIANOV, STANISLAV Y, ETHIER, C ROSS · 2019 to 2022
$2.3M
NEI NIH HHS R01 EY025643NEI NIH HHS R01 EY030071NEI NIH HHS R01 EY031710
6 · The paper itself

Abstract

Glaucoma is the leading cause of global irreversible blindness, necessitating research for new, more efficacious treatment options than currently exist. Trabecular meshwork (TM) cells play an important role in the maintenance and function of the aqueous outflow pathway, and studies have found that there is decreased cellularity of the TM in glaucoma. Regeneration of the TM with stem cells has been proposed as a novel therapeutic option by several reports over the last few decades. Stem cells have the capacity for self-renewal and the potential to differentiate into adult functional cells. Several types of stem cells have been investigated in ocular regenerative medicine: tissue specific stem cells, embryonic stem cells, induced pluripotent stem cells, and adult mesenchymal stem cells. These cells have been used in various glaucoma animal models and ex vivo models and have shown success in IOP homeostasis and TM cellularity restoration. They have also demonstrated stability without serious side effects for a significant period of time. Based on current knowledge of TM pathology in glaucoma and existing literature regarding stem cell regeneration of this tissue, we propose a human clinical study as the next step in understanding this potentially revolutionary treatment paradigm. The ability to protect and replace TM cells in glaucomatous eyes could change the field forever.

Indexed as

GlaucomaInduced Pluripotent Stem CellsMesenchymal Stem CellsAnimalsHumansIntraocular PressureRegenerationTrabecular MeshworkGlaucomaStem cellsTrabecular meshwork regeneration

Identifiers

PMID35398015
PMCPMC9464663
OpenAlexW4223412735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.